A DNA intercalate with anti-tumor properties is being synthesized in this research. The drug's DNA Topoisomerase II poisonous properties allows it to bond better to DNA base pairs causing an interruption during DNA replication, which eventually leads to apoptosis. This would allow patients to intake a lower dosage causing less side effects than existing cancer treatments.